Provided by Tiger Trade Technology Pte. Ltd.

CytoDyn Inc.

0.2447
-0.0147-5.68%
Volume:1.82M
Turnover:454.91K
Market Cap:306.79M
PE:-7.55
High:0.2600
Open:0.2600
Low:0.2403
Close:0.2595
52wk High:0.4470
52wk Low:0.1925
Shares:1.25B
Float Shares:1.25B
Volume Ratio:0.76
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0324
EPS(LYR):-0.2868
ROE:1659.17%
ROA:-70.67%
PB:-2.56
PE(LYR):-0.85

Loading ...

Company Profile

Company Name:
CytoDyn Inc.
Exchange:
OTCQB
Establishment Date:
2002
Employees:
13
Office Location:
1111 Main Street,Suite 660,Vancouver,Washington,United States
Zip Code:
98660
Fax:
360 799 5954
Introduction:
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.